Dbv Technologies S A Stock Price, News & Analysis

DBV Technologies announced plans to begin a pivotal Phase 3 study for its modified Viaskin Peanut patch aimed at children. This follows FDA feedback suggesting a sequential development approach, which DBV deemed inefficient. Instead, the company will conduct a Phase 3 placebo-controlled trial to demonstrate the patch's safety and effectiveness. In parallel, DBV has withdrawn its Marketing Authorization Application for Viaskin Peanut from the EMA due to insufficient data from a single pivotal study. The company believes that new data will better support its application for regulatory approval.

DBVT reported its monthly update on voting rights and share count as of November 30, 2021. The total number of shares stands at 55,090,362, indicating a consistent share base. The total number of voting rights is 55,090,362 gross and 54,983,362 net, after accounting for shares without voting rights. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, ensuring transparency for investors and stakeholders.

DBV Technologies, a clinical-stage biopharmaceutical company, announced participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021. CEO Daniel Tassé will engage in a fireside chat at 8am ET. A live webcast will be available on the company’s website, with a replay following the event. DBV Technologies is focused on developing Viaskin, a proprietary platform aimed at food allergy treatment through epicutaneous immunotherapy. The company's shares are traded on Euronext and Nasdaq under symbols DBV and DBVT, respectively.

DBVT has released information on the total number of voting rights and shares as of October 31, 2021. The company has a total of 55,011,687 shares, with 54,910,187 voting rights net of non-voting shares. This report complies with Article 223-16 of the General Regulations set by Autorité des Marchés Financiers. The data is crucial for shareholders and potential investors as it reflects the company's governance structure and shareholder engagement.

DBV Technologies announced it will present new long-term data from the REALISE trial at the ACAAI 2021 Annual Scientific Meeting, Nov. 4-8, 2021. The study focuses on the safety and health-related quality of life impacts of its lead product, Viaskin™ Peanut (DBV712), in children aged 4-11. An oral presentation and a poster presentation will showcase key findings from three years of data. The company aims to demonstrate the potential real-world applications of Viaskin Peanut, which targets peanut allergy treatment through a novel epicutaneous patch technology.

DBV Technologies reported its third quarter 2021 financial results on October 26, 2021, showing a net loss of $24.0 million, a decrease from $31.0 million in Q3 2020. Cash and cash equivalents fell to $98.2 million from $196.4 million at the end of 2020. Operating expenses decreased by 24% to $25.7 million, primarily due to cost containment measures and workforce reduction. Regulatory updates indicate the FDA is reviewing data before the STAMP trial can proceed, while EMA discussions are ongoing regarding Viaskin Peanut's Marketing Authorization.

DBVT announced its monthly update on voting rights and total shares as of September 30, 2021. The company disclosed a total of 55,011,687 shares outstanding, with 54,936,287 shares having voting rights. This report follows Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The data is crucial for shareholders and investors to monitor ownership and voting power within the company.

DBVT announced the voting rights and total shares as of August 31, 2021. The company holds 55,011,687 total shares, with a total gross of 55,011,687 voting rights and a total net of 54,963,687 voting rights, accounting for shares without voting rights. This data is provided in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The shares are listed on the NYSE Euronext Paris market, under the ISIN Code: FR 0010417345.

DBV Technologies (DBVT) has announced participation in several virtual investor conferences in September 2021. The events include the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, followed by Citi's 16th Annual BioPharma Virtual Conference on September 8. Additionally, a pre-recorded fireside chat will be made available on September 13 at 7:00 AM ET during the H.C. Wainwright 23rd Annual Global Investment Conference. Investors can access the webcast and replay on the company’s website.